FLAIR: Week 124 Results of Long-Acting Injectable Cabotegravir + Rilpivirine

Source: The 11th International AIDS Society Conference on HIV Science
Download Slideset
July 18-21, 2021; Virtual
At Week 124, 80% of patients still demonstrated virologic suppression on monthly injectable cabotegravir + rilpivirine, with no new safety signals since the Week 96 analysis.
Format: Microsoft PowerPoint (.ppt)
File Size: 257 KB
Released: July 21, 2021

Acknowledgements

Provided by Clinical Care Options, LLC
Contact Info

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Produced in collaboration with
Supported by educational grants from
Gilead Sciences, Inc.
Janssen Therapeutics, Division of Janssen Products, LP
Merck Sharp & Dohme Corp.
ViiV Healthcare

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings